Centessa Pharmaceuticals-adr (CNTA)
$15.8
Live
Performance
- $15.73$16.25$15.80
0.47%
Downside
Day's Volatility :3.2%
Upside
2.74%
- $5.58$17.59$15.80
64.66%
Downside
52 Weeks Volatility :68.26%
Upside
10.18%
Returns
| Period | Centessa Pharmaceuticals-adr | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 70.74% | 3.6% | 0.0% |
6 Months | 60.5% | 10.2% | 0.0% |
1 Year | 147.3% | 19.6% | 0.0% |
3 Years | -3.25% | 16.8% | -23.0% |
Highlights
Market Capitalization | 2.0B |
Book Value | $2.54 |
Earnings Per Share (EPS) | -1.55 |
Wall Street Target Price | 26.14 |
Profit Margin | 0.0% |
Operating Margin TTM | -2268.45% |
Return On Assets TTM | -24.54% |
Return On Equity TTM | -55.84% |
Revenue TTM | 6.9M |
Revenue Per Share TTM | 0.07 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -155.1M |
Diluted Eps TTM | -1.55 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.63 |
EPS Estimate Next Year | -1.71 |
EPS Estimate Current Quarter | -0.39 |
EPS Estimate Next Quarter | -0.4 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 65.44%
Technicals Summary
Sell
Neutral
Buy
Centessa Pharmaceuticals-adr is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Centessa Pharmaceuticals-adr | 3.08% | 60.5% | 147.3% | -3.25% | -26.81% |
 Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
 Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
 Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
 Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Centessa Pharmaceuticals-adr | NA | NA | NA | -1.63 | -0.56 | -0.25 | NA | 2.54 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Centessa Pharmaceuticals-adr | Buy | $2.0B | -26.81% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Centessa Pharmaceuticals-adr
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 48.1%
Institutional Holdings
Medicxi Ventures Management (Jersey) Ltd
15.53%General Atlantic Llc
7.53%EcoR1 Capital, LLC
4.44%First Light Asset Management, LLC
3.72%Perceptive Advisors LLC
3.06%Vida Ventures Advisors, LLC
3.06%
Company Information
centessa pharmaceuticals plc is a next-generation biopharmaceutical company that aims to reshape the traditional drug development process. the company applies an asset-centric r&d model at scale to advance a portfolio of highly validated programs led by industry leading teams. each program is developed by a centessa subsidiary and supported by a centralized infrastructure and the centessa management team. the company is headquartered in cambridge, mass.
Organization | Centessa Pharmaceuticals-adr |
Employees | 72 |
CEO | Dr. Saurabh Saha M.D., Ph.D. |
Industry | Healthcare |
Discover More
Lantern Pharma Inc
$15.80
-1.56%
Surmodics Inc
$15.80
-1.56%
Precigen Inc
$15.80
-1.56%
Redhill Biopharma Ltd-sp Adr
$15.80
-1.56%
Mind Medicine (mindmed) Inc
$15.80
-1.56%
Sonida Senior Living Inc.
$15.80
-1.56%
22nd Century Group Inc
$15.80
-1.56%
Enhabit Inc
$15.80
-1.56%
Kiniksa Pharmaceuticals International Plc
$15.80
-1.56%